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SapropterinPhenylketonuria (PKU) is an inherited disorder of phenylalanine (Phe) metabolism. Until recently, the only
treatment for PKU was a Phe-restricted diet. Increasing evidence of suboptimal outcomes in diet-treated in-
dividuals, inconsistent PKU management practices, and the recent availability of tetrahydrobiopterin (BH4)
therapy have fueled the need for new management and treatment recommendations for this metabolic dis-
order. BH4, now available as sapropterin dihydrochloride (sapropterin), may offer the potential for improved
metabolic control as well as enhanced dietary Phe tolerance in some PKU patients. A group of metabolic di-
etitians from North America convened in June 2011 to draft recommendations for the use of sapropterin ther-
apy in PKU. Physicians with extensive experience in PKU management were invited at a later date to
contribute to the development of these recommendations. Based on extensive clinical experience and current
evidence, the present recommendations provide guidance from patient selection and determination of
sapropterin response to the long-termmanagement of patients on sapropterin therapy. Target Phe levels, nu-
tritional adequacy, neurocognitive screening and adherence to treatment are addressed to optimize patient
outcomes.
© 2012 Elsevier Inc. All rights reserved.1. Introduction
Phenylketonuria (PKU; OMIM ID: 261600 and 261630) is an auto-
somal recessive metabolic disorder characterized by elevated phe-
nylalanine (Phe) levels in the blood and other tissues. This inborn
error of Phe metabolism is caused by deficient activity of phenylalanine.S. and S.P. are employees of
KUVAN® (sapropterin dihy-
nd S.C. have received research
thors have received honoraria
).
rights reserved.hydroxylase (PAH; EC 1.14.16.1), the enzyme that catalyzes the
hydroxylation of L-Phe to L-tyrosine [1]. Over 500 mutations in the
phenylalanine hydroxylase gene (PAH) have been identified, giving rise
to wide genotypic and phenotypic heterogeneities [2].
If left untreated, PKU can lead to profound mental retardation, sei-
zures, behavioral problems and other symptoms. Newborn screening
for PKU enables early diagnosis and dietary intervention and the
subsequent prevention of the most severe sequelae. Most clinics
worldwide advocate lifelong adherence to a Phe-restricted diet to
maintain blood Phe concentrations within recommended treatment
ranges. The Phe-restricted diet excludes high-protein natural foods
such as meat, dairy products, legumes, nuts and eggs. Limited
amounts of Phe-containing intact protein are allowed from calculated
amounts of breads and other starchy foods. Remaining protein needs
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foods. Fruits, vegetables, fats, sugars and specially modified low-
protein food like breads, pasta, and baked products provide needed
energy sources and enhance the quality and variety of food allowed.
However, adherence to this highly restrictive and often socially
burdensome diet is a significant challenge for many PKU patients,
particularly during adolescence and in adulthood [3]. Furthermore,
increasing evidence suggests that even PKU individuals treated early
and continuously with diet alone may be at risk for suboptimal
neurocognitive, psychosocial and nutritional outcomes compared to
unaffected peers [4].
Tetrahydrobiopterin (BH4), a cofactor of PAH, can lower elevated
blood Phe levels in a subset of patients with PAH deficiency [5–7].
Sapropterin dihydrochloride (sapropterin), a synthetic formulation
of the 6R-isomer of BH4, has been available as a non-dietary therapy
option for patients with BH4-responsive PKU since 2007 in the United
States, 2008 in the European Union, and 2010 in Canada. Sapropterin
is a well-tolerated oral medication that can be used as an adjunct to a
Phe-restricted diet to reduce elevated blood Phe levels in patients
who respond to this therapy [8,9]. For some patients, sapropterin
may also increase dietary Phe tolerance to enable consumption of
larger amounts of natural protein [10].
Recommendations for determining response to sapropterin and
its use in PKU were published by Levy et al. in 2007 [11]. In the fol-
lowing year, Singh and colleagues published recommendations for
the dietary management of sapropterin-responsive PKU patients
[12]. Both sets of recommendations were consistent with the study pro-
tocols leading to FDA approval of sapropterin. In 2009, the European
working group on PKU described a protocol for optimizing sapropterin
use in PKU management [13]. New evidence and insight from more re-
cent clinical experience as well as recognized inconsistencies in saprop-
terin use across clinics have prompted the need for a practical and
comprehensive set of recommendations for the management of PKU
patients on sapropterin therapy. A group of metabolic dietitians from
clinics across North America convened in Portland, Oregon, USA in
June 2011 to discuss current clinical practices and to develop practical
recommendations for various aspects of sapropterin use in PKU, from
patient selection and determination of response to the long-term man-
agement of patients on therapy. Physicians with expertise in PKU treat-
ment and management were invited at a later date to participate in the
formulation of these recommendations and to provide input onmedical
management. The discussion of common clinical practices and rec-
ommendations presented here is a result of this effort and is based on
the most current available evidence and the broad range of clinical
experience of the author practitioners. Key issues in PKU management
are addressed within these recommendations, including optimal Phe
levels, nutritional adequacy, neurocognitive testing, and adherence to
treatment.
2. Formulation of recommendations
A group of metabolic dietitians who practice in various clinics
across the United States and Canada convened for a day in Portland,
Oregon, in June 2011 to initiate the development of recommenda-
tions for the use of sapropterin in PKU. This meeting was sponsored
by BioMarin Pharmaceutical Inc. (BioMarin). Current clinical practices
were reviewed and discussed and a preliminary outline of recom-
mendations was drafted during the meeting. A review of the liter-
ature was conducted to identify and gather relevant evidence.
Continuing discussions and ongoing refinement of the working docu-
ment revealed a need for the inclusion of medical management con-
siderations, and in the fourth quarter of 2011, several physicians
with experience in PKU management were invited to contribute to
the development of the recommendations. Draft recommendations
were circulated via email to all contributors and their comments and
revisions were reviewed and integrated. The final recommendationswere approved by all authors prior to submission toMolecular Genetics
and Metabolism for publication.
While the recommendations presented here reflect a broad con-
sensus among this group of clinicians, areas of disagreement regard-
ing some practice decisions remain. It is not within the authors'
ability to resolve inconsistencies across clinics where consensus is
still lacking. One intention of this work is to bring issues that lack con-




A trial of sapropterin may be offered to all patients with PKU to de-
termine clinical benefit. A patient's history and current circumstances
should be considered to ensure that the patient is able to adhere to
the treatment protocol over the 1–2 month trial period. Patients and
families should be prepared for the possibility that sapropterin thera-
py may not be beneficial. Financial/insurance considerations should
be addressed.
Special consideration is warranted for the following patient
populations:
(i) Mild hyperphenylalaninemia
Currently there is considerable debate among clinicians regard-
ing the need to treat individuals with hyperphenylalaninemia
who have persistent blood Phe levels below 600 μmol/L even
when catabolically challenged [14–17]. While there is a clear
need to address the dearth of research on treatment of patients
with mild hyperphenylalaninemia, there is some evidence from
studies on treated patients with classical and less severe PKU to
suggest that neurocognitive outcomes are optimized when
blood Phe is maintained at levels below 360 μmol/L [18–23].
Patients withmilder forms of PKU have been found to have higher
rates of response to sapropterin (≈50–80%) compared to patients
with classical PKU (≈10%) [13]. Because response to sapropterin
may be observed in patients throughout the spectrum of PKU
classification, patient selection for a trial should be based on the
potential for clinical benefit to an individual patient, without re-
gard to anticipation of ability to respond. Patients with blood
Phe concentrations in the range of 360–600 μmol/L, particularly
those with suboptimal cognitive and psychosocial functioning,
should be considered for a trial of sapropterin.
(ii) Infants and young children
Although clinical trials of sapropterin did not include subjects
younger than 4 years of age, a recent study suggests that the
medication can be used safely and effectively in patients within
this age range [24]. Moreover, BH4 loading tests are routinely
performed on infants in many PKU centers in Europe [25] and
Canada. A trial may be considered for all infants (0–2 years of
age) with pretreatment Phe levels above 360 μmol/L. Saprop-
terin may enable infants who respond to be fed exclusively
with breast milk (which has a lower Phe content than com-
mercial infant formulas) or may allow a greater proportion
of intact protein to be derived from breast milk or infant for-
mula. The introduction of a small amount of medical food
should be encouraged, however, in order to increase the like-
lihood of its acceptance later in life if needed. Detecting an
adverse reaction in very young patients who cannot describe
discomfort is a challenge that should be considered prior to
initiating treatment. Additional recommendations may be re-
quired when more experience has been obtained using saprop-
terin in infants with PKU. There is currently a long-term open
label study underway that is evaluating the safety and efficacy
of sapropterin in children who are 0–6 years of age [26,27].
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considered for a trial of sapropterin. The benefits of initiating
therapy in children of this age group include the potential to im-
prove metabolic control during this critical time of growth and
development, the potential to increase natural protein intake
early in life, and the greater likelihood of adherence to treat-
ment. Conducting an accurate sapropterin trial during these
years may be challenging, however, because as children grow
and protein needs change, it may be difficult to definitively attri-
bute a reduction in blood Phe levels and/or an increase in Phe
tolerance to sapropterin responsiveness. An extended trial may
be required to determine if a change in blood Phe indicates a
temporary response due to the increased anabolism during
growth or a more stable and long-lasting effect due to saprop-
terin responsiveness. Furthermore, as young children are less
likely than adolescents and adults to develop an aversion to
medical food and more likely to adhere to a Phe-restricted diet
[3], postponing a trial for sapropterin response may be consid-
ered in 2–4 year old patients who exhibit good metabolic con-
trol with dietary therapy alone. This also allows a time period
during which parents can educate their child on skills needed
to maintain dietary restrictions. The decision to initiate or defer
sapropterin treatment should be made jointly by clinicians and
families and should balance the advantages and disadvantages.
(iii) Pregnant women
The use of sapropterin has not been evaluated in pregnant
women in controlled trials. Good maternal blood Phe control
and normal neonatal outcomes have been reported in several
case studies of sapropterin use in pregnancy [28–31]. Saprop-
terin is designated as a Pregnancy Category C drug due to the
lack of well-controlled studies [32]. The use of Category C
drugs may be justified when a known significant risk to the
mother or the fetus can be reduced. To prevent the teratogenic
effects associated with hyperphenylalaninemia due to untreated
or poorly treated maternal PKU, women with PKU should main-
tain blood Phe levels between 120 and 360 μmol/L prior to and
throughout pregnancy [33]; however, achieving this level of
metabolic control may be difficult [34–36]. The initiation of
sapropterin therapy during pregnancy should be considered if
strict dietary management to maintain blood Phe levels within
the recommended range is unattainable or if dietary therapy
has been discontinued or relaxed during the years before con-
ception. Ideally, a sapropterin trial should be performed prior
to pregnancy because Phe tolerance increases during pregnancy
which may compromise the ability to reliably evaluate a re-
sponse to sapropterin. For women receiving sapropterin therapy
who become pregnant, the continued use of sapropterin during
pregnancy may be beneficial due to the known risk of increased
blood Phe levels that may result from discontinuing therapy.
Pregnant women with PKU should be informed about the classi-
fication of sapropterin as a Category C medication and should
consent to its use during pregnancy.
(iv) Late-treated and untreated adults
Many PKU individuals who were born before newborn screen-
ing was introduced in the 1960s were diagnosed late and have
severe mental retardation and behavioral problems. For these
mentally impaired patients, a reduction in blood Phe levels
and possible improvements in behavior may be achieved with a
Phe-restricted diet, but dietary treatment may be difficult to im-
plement [37]. Anecdotal evidence suggests that sapropterin ther-
apy may reduce blood Phe levels and/or improve behavior (e.g.
reduce anxiety or nervousness) in late-treated and untreated
PKU adults [38,39], but sufficient documentation regarding effi-
cacy in this population is still lacking. Successful response to
sapropterin based on blood Phe reduction alone may be difficult
to determine in individuals who may realistically be unable toadhere to diet or the trial protocol; in such cases, a decision on
benefit may be made based on input from the patient's mental
health specialist and/or on validated tools designed to assess im-
provement in behavior in compromised patients [40]. Special
issues to consider prior to initiating a trial include the concomi-
tant use of psychotropic drugs and methods of assessing re-
sponse and adverse events in non-verbal patients. Based on
the experience of some of the authors, severely affected PKU
adults may react to the introduction of sapropterin with a tem-
porary increase in behavioral problems (e.g. anxiety), but this
effect may be reduced or avoided by using a lower starting
dose (i.e. 5–10mg/kg/day) and increasing the dose gradually
over a longer trial period.
All patients selected as potential candidates for sapropterin thera-
py should be informed that for the duration of the trial period they
will be expected to provide more frequent blood samples, record die-
tary intake, and stay in contact with the clinic. The willingness and
ability of patients/families to comply with clinic requirements should
be carefully evaluated in order to ensure an accurate trial for re-
sponse. In certain situations where family members may be unable
to fully engage in the patient's care (e.g. dysfunctional households,
joint-custody arrangements), the involvement of an alternative care-
giver or other responsible adult, such as a school teacher or school
nurse, could be considered. Special attention should be given to
patients and families who are considered to be at higher risk of non-
compliance; risk factors include low socioeconomic status, low edu-
cational achievement, illiteracy or language barriers, co-morbidities
or other disabilities, and unemployment. Finally, a trial should not
be started if the patient's health is compromised (e.g. by illness,
poor nutrition, or stress) or if the patient is undergoing any lifestyle
changes (e.g. a new job or school, a new exercise routine) because
these circumstances may interfere with the patient's ability to follow
the clinical protocol and prevent reliable determination of a blood
Phe response to sapropterin.
3.2. Baseline assessment
A careful and thorough initial evaluation of the patient is essential
for ensuring an accurate trial of sapropterin responsiveness. The eval-
uation should be comprehensive and include obtaining a complete
medical history, performing a physical examination, collecting base-
line laboratory and dietary intake data, and identifying cognitive def-
icits and psychosocial factors that may compromise adherence to
treatment.
The following assessments, most of which are important in the
routine care of PKU patients, are recommended prior to the start of
a sapropterin trial and summarized in Table 1:
• Blood Phe concentrations—Ideally, 3 or more blood Phe levels
should be obtained within the month prior to the start of the trial.
Every effort should be made to ensure that blood samples are
obtained by the same method and at a consistent time of day that
is at least 2h after food intake. More data should be obtained if ini-
tial blood Phe levels are inconsistent or if the methods used for test-
ing blood Phe differ (i.e. filter paper fluorometric, venous HPLC,
etc.). The purpose of obtaining multiple blood Phe levels is to deter-
mine the normal range of variation in an individual patient before
the trial. It is recommended to use the same analytical assay each
time a blood Phe level is obtained. If baseline blood Phe levels are
low (b120–240 μmol/L), increasing dietary Phe intake prior to the
trial may be considered to ensure that increases in Phe tolerance can
be attributed to sapropterin response and not to over-restriction of
Phe.
• Dietary intake—Patients should be instructed not to change their
eating habits prior to a trial of sapropterin unless directed to do so
Table 1
Recommended assessments for PKU patients on sapropterin therapy. Most of these as-
sessments are recommended for routine care of all individuals with PKU.
Baseline Sapropterin trial Long-term therapy
Blood Phe levels X X X
Dietary intake X X X
Medical history X
Physical examination X X
Weight, height X X X
Nutritional status X X X
Metabolic statusa X X X
Dietary Phe tolerance X X X
Mental health screening X X X
Adverse reactions X X
Pregnancy status X X X
Illness X X X
Concomitant medications X X X
Changes to daily routine X X X
Adherence to treatment X X X
a Blood Phe/Tyr, plasma amino acids.
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questionnaire (FFQ) [41] should be completed prior to each blood
test and used to estimate nutrient intake and assess nutritional sta-
tus. The choice of assessment tool should be based on the willing-
ness and abilities of the patient. Patient burden can be high for
food records, which require time and thought to complete, and
the act of maintaining records may affect eating behavior. The FFQ
method typically requires less patient burden than the 3-day diet
record and may be more appropriate for patients who may have
difficulties with completing more detailed assessments. Diet
counseling prior to the trial should be considered for patients with
suboptimal nutritional status. For vegetarian patients who are not
consuming medical food, dietary counseling may be appropriate
to improve nutritional adequacy prior to the trial. When significant
dietary changes prior to the trial are considered essential for im-
proving nutritional adequacy, the trial should be postponed in
order to ensure that a change in blood Phe is not due to changes
in dietary intake.
• Medications and supplements—Concomitant use of drugs that in-
hibit folate metabolism (e.g. methotrexate), drugs that affect nitric
oxide-mediated vasorelaxation (e.g. PDE-5 inhibitors), and levodo-
pa require caution [32].
• Medical history—For patients with a history of gastrointestinal dis-
orders, particular attention should be paid to the administration of
sapropterin. The medication should be taken with food, and starting
with lower doses may ameliorate gastrointestinal distress, which
has been reported as an adverse event [42]. More frequent monitor-
ing during the trial should be considered. Previous allergic reactions
to medications should be noted.
• Pregnancy status—For women who are pregnant or planning a
pregnancy, a sapropterin trial should be considered if dietary man-
agement alone does not adequately control blood Phe levels or if di-
etary adherence is problematic. These patients should be informed
that sapropterin is a Category C medication.
• Mental health screening—When possible, patients should be screened
for cognitive impairment and psychosocial problems, which may im-
pact adherence to treatment. Appropriate screening tools can include
the Behavior Rating Inventory of Executive Function (BRIEF) [43]
and the Pediatric Symptom Checklist (PSC) [44] for children, and
the BRIEF and Brief Symptom Inventory (BSI) [45] for adults
[46,47]. If these tools are not available or are impractical to admin-
ister, then feedback from patients and their teachers, spouses, and
employers may be helpful for assessment. If relevant, input from a
patient's mental health specialist should also be used to determine
benefit. Referral to a mental health specialist should be considered
if warranted.• Physical examination—A routine physical examination should be per-
formed, and anthropometric data (weight, height, and, for children
under 3 years of age, occipitofrontal circumference (OFC)) collected.
• Complete blood count and blood chemistry profile—A complete
blood count as well as appropriate blood tests to determine nutri-
tional and metabolic status (e.g. RBC folate, vitamin B12, ferritin, al-
bumin, 25-hydroxyvitamin D, prealbumin, plasma amino acids,
essential fatty acids) should be obtained if these have not been per-
formed within one year.
• Adherence to treatment—The patient's ability to comprehend instruc-
tions and to adhere to the clinic protocol (e.g. keep diet records, check
Phe levels) should be assessed. Barriers to adherence should be iden-
tified and addressed accordingly.
3.3. Patient education prior to a sapropterin trial
Before initiation of the trial, patients should be counseled on the
common side effects of sapropterin and the clinic protocol for the
trial, including how to take sapropterin and the importance of timely
submission of blood samples. They should be informed that any
changes to diet or lifestyle may invalidate the trial and should there-
fore be avoided. The importance of adherence prior to and during
treatment should be emphasized and appropriate interventions to
enhance adherence should be considered; for example, patients
may receive phone or email reminders to obtain blood Phe tests and
to submit blood test results and diet records. Information should be
tailored to the age and cognitive ability of the patient. For patients
new to clinic or who have not been seen for an extended period, ide-
ally at least two initial clinic visits prior to the trial are recommended
in order to establish a supportive relationship.
The following materials and tools are recommended for patient
use prior to and during a sapropterin trial:
• Educational materials about sapropterin (e.g. how it works, its safe-
ty and efficacy)
• Clinic-specific instruction sheet detailing how to take and store
sapropterin, and how to contact the PKU clinic for questions or
concerns
• Educational video or in-clinic demonstration on how to perform a
blood Phe test
• Lab slips/filter papers
• Diet records/FFQ forms
• Calendar to remind patients to take medication
• Diary to record sapropterin intake, diet, behavioral changes, and/or
adverse events
• Weekly pill box
3.4. Implementation of sapropterin
An initial dose of 20mg/kg/day is recommended. A lower starting
dose (5–10mg/kg/day) may be considered in infants or patients
with gastrointestinal issues or other risk factors (e.g. concomitant
drugs). The dose may be titrated between 5 and 20mg/kg/day to
achieve optimal clinical benefit. For obese and overweight patients,
an initial dose based on adjusted body weight rather than actual
body weight may be recommended; however, if this is deemed inef-
fective, the dose should be increased to reflect actual weight [48].
Splitting the total dose should be considered if taking a large number
of tablets is difficult for the patient or if a patient experiences gastro-
intestinal issues.
Sapropterin is recommended to be administered orally once daily,
at the same time each day, and with a meal. Ideally the medication
should be taken with the meal of the day that contains the greatest
amount of Phe. Because sapropterin is acidic, it is better absorbed
and tolerated with food and may be less effective when taken with
medical food alone. The tablets may be swallowed whole, crushed
273A. Cunningham et al. / Molecular Genetics and Metabolism 106 (2012) 269–276and dissolved in water, apple juice or other appropriate beverage, or
crushed and mixed in soft foods. For infants and young children,
sapropterin may be more effectively administered by mixing crushed
tablets in formula or soft food or by administering dissolved tablets
via syringe with a feeding.
3.5. Patient monitoring during a sapropterin trial
The patient's health and response to sapropterin as well as factors
that may invalidate the trial should be evaluated throughout the trial
period (Table 1). Patient monitoring should include:
• Blood Phe concentrations—Blood Phe tests should be performed
prior to initiation of treatment and weekly thereafter until comple-
tion of the trial. For infants and young children, a blood Phe test is
best obtained at day 1 or 2 of the trial; more frequent monitoring
is recommended for this age group in order to avoid Phe deficiency.
Blood samples should be obtained at a consistent time of day that is
at least 2h after food intake in order to minimize any impact of di-
urnal fluctuation or dietary Phe ingestion on blood Phe level. The
same analysis method to determine blood Phe levels should be
used throughout the trial period. Patients should be informed that
regular blood Phe testing is required to evaluate responsiveness
and to determine proper dosage.
• Dietary intake—Patients should be instructed to maintain their
usual diet during the trial period in order to ensure an accurate
trial for response. Dietary intake should be assessed prior to each
blood Phe test if possible.
• Mental health—Patients should be encouraged to record their mood
and sense of well-being in a diary throughout the course of the trial.
If possible, a follow-up evaluation of cognitive and psychosocial
functioning should be conducted at approximately 4 weeks using
appropriate screening tools. Obtaining input from third party ob-
servers such as teachers, spouses, and employers is beneficial. For
patients being followed by a psychologist or psychiatrist, consider
contacting their mental health specialist for input.
• Weight—Patients should be counseled on the importance of weight
maintenance during the trial period. Changes in weight may affect
response to sapropterin as dosing is based on weight. For young
patients who are growing, weight gain or loss outside of the nor-
mal growth rate may affect the validity of the trial and necessitate
adjustments to sapropterin dose. Weight should be monitored
throughout the duration of the trial, and more frequently in youn-
ger patients.
• Adverse events—Patients should be educated on the most common
side effects of sapropterin and should be assessed for any signs and
symptoms of an adverse reaction at every clinic visit. Since adverse
events may be difficult to determine in infants and very young chil-
dren who do not have the ability to verbally describe discomfort, it
is important to counsel families to watch closely for any signs of ir-
ritability and intolerance. Any patient experiencing an adverse reac-
tion should be treated appropriately and closely monitored until
symptoms have stabilized or subsided. The adverse events associat-
ed with sapropterin have been reported to typically be mild and pri-
marily associated with gastrointestinal issues or headache [42].
• Adherence to treatment—Barriers to adherence may arise at any
point during the trial period. Reasons for nonadherence should be
identified (e.g. failure to understand dosing instructions, adverse
reaction, psychosocial problem) and addressed accordingly.
• Illness—Patients who become ill during the trial should be closely
monitored and examined to determine if symptoms are related to
the medication. For patients with mild symptoms, the trial does
not necessarily need to be stopped, but may need to be extended
to reliably evaluate responsiveness.
• Changes to daily routine—Patients should be instructed not to make
any lifestyle changes (e.g. starting a new exercise regimen or a newjob, traveling) during the trial period which may lead to changes in
blood Phe and invalidate the trial for response.
3.6. Dietary phenylalanine challenge
If a patient responds to sapropterin with a clinically meaningful
reduction in blood Phe (discussed in the next section) and consistent
Phe concentrations within the targeted range, a dietary Phe challenge
should be considered. During any period of dietary adjustment, blood
Phe must be regularly monitored and the diet assessed for adequate
intake of calories, protein, vitamins and minerals.
3.6.1. Determination of dietary Phe tolerance
Dietary Phe can be added to the patient's food or medical food in
the form of dry or liquid milk; if lactose intolerance is noted, egg
white powder or soy milk can be used instead. This approach allows
controlled increases of dietary Phe in a form that is accurately mea-
sured and does not involve introducing high Phe foods that may
need to be discontinued if there is no significant increase in Phe toler-
ance. These products should be gradually added to the diet, and in
suggested increments of 10% of usual Phe intake or in increments of
50mg/day (for children) or 100mg/day (for adults). If dietary Phe tol-
erance increases markedly, increments of added Phe may need to be
larger in order to evaluate total tolerance without extending the
trial period unduly. Medical food intake should remain unchanged
to avoid any effect on blood Phe levels other than adding dietary
Phe. Blood Phe should be frequently monitored and dietary Phe
should be adjusted weekly until blood Phe concentrations are main-
tained within the individualized target range over a 4-week period.
If dietary Phe tolerance increases substantially, the amount of dry or
liquid milk required to achieve maximum tolerance may become dif-
ficult for the patient to consume, especially if it is added to medical
food formulas. Natural foods may then need to be introduced as
well; in these cases, it is recommended to utilize foods that are con-
sistently pre-portioned (e.g. eggs, pre-packaged cheese slices, yogurt,
etc.). To ensure that Phe tolerance is maximized in well-controlled
patients who are able to maintain Phe levels within the targeted
range with diet alone, it may be advisable to increase dietary Phe
until blood Phe levels are just above the recommended range [49]; di-
etary Phe can then be adjusted downward to achieve blood Phe in the
targeted range.
The process described above represents the most well controlled
approach to determining dietary Phe tolerance and may not be feasi-
ble to implement in every clinical situation. A less accurate determi-
nation of dietary Phe tolerance may be achieved through a less
controlled advancement of dietary Phe using foods that are already
being consumed; for example, if a person derives 10g of protein
from food, then an incremental increase of 10% of usual Phe intake
may be roughly equivalent to adding half a slice of bread (≈1g
protein).
3.6.2. Diet modification
After the patient's dietary Phe tolerance with sapropterin has been
established, the dry or liquid milk (or other product(s) used to trial
tolerance) may be gradually replaced with natural foods. Dietary
modification should be an incremental process, beginning with the
replacement of modified low protein food products (e.g. bread,
pasta, cereal) with regular foods. If these substitutions are not suffi-
cient to fulfill an increased dietary Phe tolerance, high-quality pro-
teins such as egg and cheese may then be introduced. Patients
should be advised that as small errors in measuring higher protein
food can result in a large increase in dietary Phe, foods that are easy
to consistently portion and measure (e.g. a cheese slice, a container
of yogurt) are preferable. Meat is not recommended as it contains
high concentrations of Phe and is difficult to consistently portion; it
is best reserved for those patients who demonstrate an increase in
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previously prohibited foods to the diet may cause anxiety in some pa-
tients/parents and should be anticipated and addressed. Additionally,
patients who develop a substantially increased Phe tolerance may
find it burdensome to manage their restriction by counting milli-
grams of Phe intake, so counting grams of protein instead may be
recommended.
3.6.3. Medical food adjustment
If dietary Phe tolerance is increased sufficiently so that age-
appropriate dietary reference intakes (DRIs) for protein are met
with natural foods, then the amount of medical food may be reduced
in 25% increments. If less than 50% of protein intake is then derived
frommedical food, high biological value protein sources should be in-
corporated in the diet to ensure adequate intake of essential amino
acids. Elimination of medical foodmay be an option for some patients,
but the decision to do so must weigh both the advantages and disad-
vantages. While medical food is expensive and inconvenient and ad-
herence can be difficult, it may provide a valuable protein source
during times when Phe intake cannot be increased (e.g. illness, pu-
berty), or if sapropterin treatment is interrupted. Discontinuing med-
ical food altogether may compromise taste acceptability if it becomes
necessary to re-introduce it in the future. Maintaining small amounts
of medical food in the dietary regime may help to avoid these poten-
tial consequences. As medical food is reduced or discontinued, blood
Phe, plasma amino acids and nutrient status should be closely moni-
tored. The need for vitamin and mineral supplements should also be
considered.
3.6.4. Patient education
Because the PKU diet allows for only a very limited choice of intact
protein sources, patients may not be adept at selecting appropriate
natural foods to ensure a nutritionally balanced diet. Patients who
have an increased Phe tolerance and are able to consume a wider
range of natural foods should be taught the basic principles of nutri-
tion as well as how to count grams of protein, read food labels, and
determine the protein content of foods when eating out. The impor-
tance of careful measurement of high-protein foods should be em-
phasized. Patients should be cautioned against excessive relaxation
of dietary restrictions and dependence on sapropterin alone to main-
tain blood Phe within therapeutic range. Patients should also be en-
couraged and educated to seek additional nutritional information
from online and other resources (e.g. the USDA website [50], Bowes
and Church's food values [51]).
3.7. Determination of clinical benefit of sapropterin
A clinically significant response to sapropterin will vary depend-
ing on the protocol of the clinical center and on individual patient sta-
tus and treatment goals. While a reduction in blood Phe is the most
widely accepted criterion for response, a survey has revealed that
other measures of response, including improvements in dietary Phe
tolerance and behavior, are being used by clinicians [52]. A clinical
benefit may be demonstrated if one or more of the following response
criteria are met:
• Reduced blood Phe concentrations—In clinical trials, a≥30% decrease
in blood Phe concentration was used to define sapropterin respon-
siveness [8,9]. However, a smaller reduction may be clinically mean-
ingful, especially if accompanied with an increase in dietary Phe
tolerance and/or an improvement in neurocognitive/psychosocial
functioning. There is currently a lack of consensus regarding which
blood Phe levels are the most appropriate to use in determining re-
sponse. Results may be best interpreted by comparing mean baseline
blood Phe to a mean of blood Phe collected during the trial, with ex-
clusion of any levels known to be associated with diet change, illness,etc. This is most relevant in patients who respond significantly and
rapidly, but may not capture slower responders. In patients who re-
spond with gradual decreases in blood Phe during the trial period, a
more effective evaluation may include the trend exhibited and/or
comparison of baseline blood Phe with final trial blood Phe. Evaluat-
ing response in a patient whose baseline blood Phe levels are be-
tween 120 and 360 μmol/L may be more difficult and a change in
dietary Phe tolerance may be a more reliable indicator of response
[53].
• Increased dietary Phe tolerance—For an accurate determination of
response, dietary Phe tolerance should be maximized prior to the
trial to ensure that any increase in tolerance of dietary Phe is due
to sapropterin and not due to over-restriction prior to the trial.
For children in periods of rapid growth, it is important to determine
if an increase in dietary Phe tolerance is due solely to sapropterin
response or if it is influenced by increased anabolism.
• Improved neurocognitive and/or psychosocial functioning—Anecdotal
reports suggest that sapropterin may improve neurocognitive and
psychosocial functioning in individuals with PKU [38,54,55]. Behav-
ioral improvements have anecdotally been associated with saprop-
terin even in the absence of a reduction in blood Phe [39], but the
mechanism for such an effect has not been elucidated. Subjective re-
ports of improvements in neurocognitive and psychosocial function-
ing are susceptible to misinterpretation and should therefore be
verified with objective clinical measures in order to ensure an accu-
rate determination of sapropterin response. Appropriate validated as-
sessments include the BRIEF, BSI, and PSC. If relevant, input from a
patient's mental health specialist may also be used to determine ben-
efit. Currently, a double-blind, placebo-controlled randomized trial is
underway to objectively evaluate the therapeutic effects of saprop-
terin on neuropsychiatric symptoms in patients with PKU [56,57].
• Improved blood Phe stability—High variability in blood Phe levels has
been associated with more severe PKU phenotypes [58]. Reduced
long-term variability of blood Phe levels may be associated with im-
proved cognitive outcomes [59]. Sapropterin has been shown to in-
crease blood Phe stability in patients with BH4-responsive PKU
[60,61]. While the mechanism of this effect has not been elucidated,
it may be related to the ability of sapropterin to enhance residual
PAH activity [5]. Stability in blood Phe concentrations should be
demonstrated over an extended period of time.
If a clinically significant response to sapropterin is not attained, it
is important to verify that factors such as illness, dietary noncompli-
ance or improper administration of sapropterin did not invalidate
the trial.
3.8. Long-term management of patients on sapropterin therapy
Optimal patient outcomes are best achieved through continuous
assessment, modification of treatment plans and monitoring by col-
laborative and multidisciplinary health care teams. Ideally, the fre-
quency of clinic visits and assessments should be tailored to meet
the individual needs of each patient.
The assessments outlined below and summarized in Table 1, many
of which are already part of routine care, are recommended for PKU
patients on long-term sapropterin therapy:
• Blood Phe concentrations—Monthly blood Phe tests are recom-
mended, but more may be required depending on age and individ-
ual patient circumstances. Patients should be informed that regular
blood Phe testing may be required for continued insurance cover-
age of sapropterin.
• Dietary intake—Ideally, dietary intake should be assessed prior to
each blood Phe test using a 3-day diet record or FFQ. Nutritional
counseling should be ongoing, particularly for patients whose
diets have been significantly modified due to increased dietary
Phe tolerance.
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ance is recommended, particularly when there are changes in
body mass or lifestyle [62].
• Metabolic status—Phe/tyrosine ratio and other plasma amino acid
levels should be monitored regularly.
• Nutritional status—Blood tests (e.g. CBC, albumin, prealbumin, ferri-
tin, vitamin D, vitamin B12, etc.) should be performed on a regular
basis to ensure nutritional adequacy.
• Mental health—Evaluations of cognitive and psychosocial function-
ing should be conducted at regular intervals if possible, particularly
as impairments can impact self-management and adherence to
treatment.
• Anthropometric measurements—Growth and changes in weight
and height should be monitored and sapropterin dose adjusted ac-
cordingly. Dietary Phe tolerance should be reassessed when body
mass changes [62].
• Adverse events—Patients should be monitored for any adverse reac-
tion to the medication on an ongoing basis.
• Illness—Elevations in blood Phe during periods of illness may re-
quire adjustments to diet and sapropterin dose.
• Pregnancy status—For patients on sapropterin therapy who become
pregnant, the continuation of sapropterin should be considered
based on the individual patient's risk for teratogenic blood Phe
levels. Pregnant women with PKU should be informed that saprop-
terin is a Category C drug and should consent to its use during preg-
nancy. The pregnancy should be closely monitored and care should
be coordinated with the patient's obstetrician.
• Adherence to treatment—Patient adherence to every aspect of treat-
ment (i.e. sapropterin therapy, diet, clinic visits, blood Phe tests, etc.)
should be continually assessed in order to optimize outcomes.
Reasons for suboptimal adherence include issues related to treat-
ment regimens (e.g. pill burden, frequency of blood tests, burden of
diet records), patient factors (e.g. cognitive or psychosocial deficits,
problems at work or home, low socioeconomic status, low education-
al level), and health system-related issues (e.g. interruptions in ac-
cess to sapropterin, inadequate access to healthcare professionals
and treatment resources). The reasons for nonadherence must be
identified in order to implement appropriate patient-specific inter-
ventions. Resources and approaches that may be utilized to enhance
adherence include:
o Peer support groups
o Family support
o Case management services
o A multidisciplinary health care team that includes a metabolic
dietitian, metabolic physician, metabolic nurse, psychologist, ge-
netic counselor, and social worker
o Improved access to clinics and healthcare providers
o Referrals to appropriate specialists (e.g. mental health)
o Phone counseling to reduce the need for multiple clinic visits
o Ongoing PKU self-management education tailored to the age and
needs of the patient
o Reminders for prescription refills, blood Phe tests, etc.
4. Conclusions
Sapropterin has the potential to improve patient outcomes in PKU
through improved control of blood Phe, possible subsequent enhance-
ments in neurocognitive/psychosocial function, and/or increased toler-
ance of dietary Phe. The recommendations described here represent an
attempt to develop a uniform and practical approach to the use of
sapropterin for treating PKU in conjunction with diet and could serve
as a useful adjunct to any future national consensus statement that
may emerge from ongoing efforts (e.g. by the National Institutes of
Health, the American College of Medical Genetics, the Health Resources
and Services Administration-funded collaboration between Genetic
Metabolic Dietitians International and Southeast Regional NewbornScreening and Genetics Collaborative) to revise current PKU manage-
ment guidelines. While these recommendations represent current
practice, experience, and knowledge regarding sapropterin treatment,
it is recognized that further experience and future research may alter
the understanding of the optimal use of sapropterin and necessitate
changes to these recommendations.
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